Comparison of FASTlab 18F-FDG production using phosphate and citrate buffer cassettes. 2013

James Z Long, and Mark S Jacobson, and Joseph C Hung
Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA.

The objective of this research is to determine whether there are significant differences in the (18)F-FDG produced by either the phosphate or the citrate buffer cassettes in the FASTlab synthesizer. METHODS Forty batches of (18)F-FDG were produced with each cassette and analyzed retrospectively. The analysis consisted of determining the mean radiochemical yield (RCY)-uncorrected and corrected for decay-radiochemical purity (RCP), pH, and residual solvent content (ethanol and acetonitrile). An independent t test (alpha error [α], 0.05) was performed to determine whether the differences were statistically significant. RESULTS The mean decay-corrected RCYs for (18)F-FDG produced by phosphate and citrate cassettes were 82.9% ± 17.4% and 79.2% ± 5.0%, respectively. The uncorrected RCY was 57.5% ± 16.7% for phosphate- and 58.8% ± 6.0% for citrate-buffered (18)F-FDG, leading to a difference of 4.4% and P value of 0.11 for corrected RCY and a difference of 2.2% and P value of 0.32 for uncorrected RCY. Thus, the RCY differences are neither statistically nor clinically significant. The mean RCPs were 99.4% ± 0.2% for the phosphate-buffered (18)F-FDG and 99.0% ± 1.1% for the citrate-buffered (18)F-FDG. There was a 0.5% difference and a P value of 0.021, meaning that the difference was statistically significant. The average pHs for (18)F-FDG produced by phosphate and citrate buffer cassettes were 5.9 ± 0.1 and 5.3 ± 0.2, respectively, resulting in a 9.6% difference and a P value close to zero (2.6 × 10(-19))-a statistically significant difference. The difference between ethanol content was also dramatic. Phosphate-buffered (18)F-FDG contained 0.08% ± 0.02% ethanol, whereas the citrate-buffered (18)F-FDG contained 0.20% ± 0.07%. No difference was found in the acetonitrile content of the 2 cassettes. CONCLUSIONS The differences in yield between cassettes are due to statistical variability. The results confirm our hypothesis that there is no significant difference in RCY. The differences seen in the statistically significant data (those with a P value > 0.05) turn out to be insignificant in a real-world setting because all values fell within the limits set by the United States Pharmacopeia and Food and Drug Administration. Therefore, determining which cassette to use is a matter of the preference of the institution.

UI MeSH Term Description Entries
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011854 Radiochemistry The study of the chemical and physical phenomena of radioactive substances. Radiochemistries
D002021 Buffers A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. Buffer
D002951 Citrates Derivatives of CITRIC ACID.
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D012997 Solvents Liquids that dissolve other substances (solutes), generally solids, without any change in chemical composition, as, water containing sugar. (Grant & Hackh's Chemical Dictionary, 5th ed) Solvent
D019788 Fluorodeoxyglucose F18 The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) 18F Fluorodeoxyglucose,18FDG,2-Fluoro-2-deoxy-D-glucose,2-Fluoro-2-deoxyglucose,Fludeoxyglucose F 18,18F-FDG,Fluorine-18-fluorodeoxyglucose,Fluorodeoxyglucose F 18,2 Fluoro 2 deoxy D glucose,2 Fluoro 2 deoxyglucose,F 18, Fludeoxyglucose,F 18, Fluorodeoxyglucose,F18, Fluorodeoxyglucose,Fluorine 18 fluorodeoxyglucose,Fluorodeoxyglucose, 18F

Related Publications

James Z Long, and Mark S Jacobson, and Joseph C Hung
October 2016, Annals of nuclear medicine,
James Z Long, and Mark S Jacobson, and Joseph C Hung
January 2008, Nuklearmedizin. Nuclear medicine,
James Z Long, and Mark S Jacobson, and Joseph C Hung
June 2022, Nuclear medicine and molecular imaging,
James Z Long, and Mark S Jacobson, and Joseph C Hung
March 2009, European journal of nuclear medicine and molecular imaging,
James Z Long, and Mark S Jacobson, and Joseph C Hung
July 1967, Die Naturwissenschaften,
James Z Long, and Mark S Jacobson, and Joseph C Hung
May 1975, Wiener klinische Wochenschrift,
James Z Long, and Mark S Jacobson, and Joseph C Hung
November 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
James Z Long, and Mark S Jacobson, and Joseph C Hung
March 2022, Bioresource technology,
James Z Long, and Mark S Jacobson, and Joseph C Hung
December 2021, Molecular imaging and biology,
James Z Long, and Mark S Jacobson, and Joseph C Hung
December 2018, Radiation protection dosimetry,
Copied contents to your clipboard!